Alexandria Venture Investments, LLC

CIK 1722024 · last filed 2023-10-16

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$96.07M

Companies

18

Total Filings

34

Lifetime Open-Market Net

$31.73M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address
26 NORTH EUCLID AVENUE
PASADENA, CA 91101
Phone
(626) 578-0777
State of Incorporation
DE
Related Filers
ALEXANDRIA REAL ESTATE EQUITIES, INC. — 13 joint filings, latest 2024-06-06
Alexandria Equities No. 7, LLC — 10 joint filings, latest 2024-06-06
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Applied Therapeutics, Inc. (APLT) Delisted 10%+ Owner 778,977 $0.10 $80.2K $29.25M 3 2023-10-16
Vigil Neuroscience, Inc. (VIGL) Delisted 10%+ Owner 192,973 $8.05 $1.55M $0 1 2022-01-11
XLO 10%+ Owner 166,423 $8.94 $1.49M $0 1 2021-10-26
Singular Genomics Systems, Inc. (OMIC) Delisted 10%+ Owner 2,645,985 $20.01 $52.95M $0 1 2021-06-01
VOR 10%+ Owner 282,804 $18.35 $5.19M $0 1 2021-02-09
ARS Pharmaceuticals, Inc. (SBTX) Delisted 10%+ Owner 699,412 $5.87 $4.11M $0 1 2020-12-08
Metacrine, Inc. (MTCR) Delisted 10%+ Owner 1,268,795 $0.49 $627.9K $500.0K 1 2020-09-18
KYMR 10%+ Owner 467,932 $110.77 $51.83M $0 1 2020-08-25
RLAY 10%+ Owner 968,365 $18.46 $17.88M $0 1 2020-07-20
RNA 10%+ Owner 502,365 $8.43 $4.23M $0 1 2020-06-16
Enliven Therapeutics, Inc. (IMRA) Delisted 10%+ Owner 293,013 $14.59 $4.28M $0 1 2020-03-16
Korro Bio, Inc. (FREQ) Delisted 10%+ Owner 956,175 $14.98 $14.32M $0 1 2019-10-09
Karuna Therapeutics, Inc. (KRTX) Delisted 10%+ Owner 214,447 $329.83 $70.73M $480.0K 1 2019-07-05
IDYA 10%+ Owner 382,384 $37.86 $14.48M $500.0K 1 2019-05-30
NXTC 10%+ Owner 197,993 $4.92 $974.1K $0 1 2019-05-13
CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted 10%+ Owner 149,637 $33.99 $5.09M $1.00M 1 2018-07-23
Evelo Biosciences, Inc. (EVLO) Delisted 10%+ Owner 594,443 $0.00 $59 $0 1 2018-05-21
X4 Pharmaceuticals, Inc (ASNS) Delisted 10%+ Owner 225,680 $0.08 $17.6K $0 1 2017-11-20

Recent Filings · Page 4 of 4

34 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2018-08-01 — Mixed +396,172 $1.50M
2018-07-23 CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted Mixed +216,304 $1.00M EDGAR
2018-05-21 Evelo Biosciences, Inc. (EVLO) Delisted Conv (C) +594,443 $0 EDGAR
2017-11-20 X4 Pharmaceuticals, Inc (ASNS) Delisted Conv (C) +225,680 $0 EDGAR
Showing 31–34 of 34
Page 4 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.